DAWN
Closed
Day One Biopharmaceuticals Inc
6.61
+0.11 (+1.69%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 6.5
Day's Range: 6.445 - 6.73
Send
sign up or login to leave a comment!
When Written:
13.37
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company that is focused on developing novel therapies for patients with genetically defined cancers. The company was founded in 2017 and is based in South San Francisco, California.
Day One's lead product candidate is DAY101, which is being developed as a potential treatment for patients with solid tumors that harbor specific genetic mutations. The company is also developing a pipeline of other targeted therapies for genetically defined cancers.
The company's approach is based on the concept of precision medicine, which involves tailoring treatments to the specific genetic characteristics of a patient's cancer. By targeting the underlying genetic drivers of cancer, Day One hopes to develop more effective and personalized treatments for patients.
Day One has raised over $200 million in funding from investors, including ARCH Venture Partners, Wellington Management, and Boxer Capital. The company is led by a team of experienced biotech executives and scientists, including CEO Jeremy Bender and Chief Scientific Officer Dr. Wen-Chien Huang.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Day One's lead product candidate is DAY101, which is being developed as a potential treatment for patients with solid tumors that harbor specific genetic mutations. The company is also developing a pipeline of other targeted therapies for genetically defined cancers.
The company's approach is based on the concept of precision medicine, which involves tailoring treatments to the specific genetic characteristics of a patient's cancer. By targeting the underlying genetic drivers of cancer, Day One hopes to develop more effective and personalized treatments for patients.
Day One has raised over $200 million in funding from investors, including ARCH Venture Partners, Wellington Management, and Boxer Capital. The company is led by a team of experienced biotech executives and scientists, including CEO Jeremy Bender and Chief Scientific Officer Dr. Wen-Chien Huang.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!